Eterna Therapeutics Stock Price Prediction
ERNA Stock | USD 0.32 0.01 3.03% |
Oversold Vs Overbought
20
Oversold | Overbought |
Wall Street Target Price 3 |
Using Eterna Therapeutics hype-based prediction, you can estimate the value of Eterna Therapeutics from the perspective of Eterna Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Eterna Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Eterna because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Eterna Therapeutics after-hype prediction price | USD 0.42 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Eterna |
Eterna Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Eterna Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Eterna Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Eterna Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
Expected price to next headline |
Eterna Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Eterna Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Eterna Therapeutics' historical news coverage. Eterna Therapeutics' after-hype downside and upside margins for the prediction period are 0.02 and 8.10, respectively. We have considered Eterna Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Eterna Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Eterna Therapeutics is based on 3 months time horizon.
Eterna Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Eterna Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eterna Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Eterna Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.09 | 7.68 | 0.17 | 0.75 | 8 Events / Month | 8 Events / Month | In about 8 days |
Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.32 | 0.42 | 32.36 |
|
Eterna Therapeutics Hype Timeline
Eterna Therapeutics is currently traded for 0.32. The entity has historical hype elasticity of 0.17, and average elasticity to hype of competition of -0.75. Eterna is estimated to increase in value after the next headline, with the price projected to jump to 0.42 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 32.36%, whereas the daily expected return is currently at -2.09%. The volatility of related hype on Eterna Therapeutics is about 2146.58%, with the expected price after the next announcement by competition of -0.43. Eterna Therapeutics currently holds 41.84 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Eterna Therapeutics has a current ratio of 3.02, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Eterna Therapeutics' use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next estimated press release will be in about 8 days. Check out Eterna Therapeutics Basic Forecasting Models to cross-verify your projections.Eterna Therapeutics Related Hype Analysis
Having access to credible news sources related to Eterna Therapeutics' direct competition is more important than ever and may enhance your ability to predict Eterna Therapeutics' future price movements. Getting to know how Eterna Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Eterna Therapeutics may potentially react to the hype associated with one of its peers.
HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
PBYI | Puma Biotechnology | 0.02 | 7 per month | 4.36 | 0.08 | 5.17 | (5.60) | 33.65 | |
IOVA | Iovance Biotherapeutics | (0.43) | 9 per month | 0.00 | (0.03) | 7.54 | (5.43) | 23.06 | |
SRPT | Sarepta Therapeutics | (3.77) | 8 per month | 2.17 | (0.04) | 3.75 | (3.33) | 17.87 | |
DAWN | Day One Biopharmaceuticals | 0.62 | 9 per month | 0.00 | (0.09) | 3.71 | (3.69) | 11.05 | |
INZY | Inozyme Pharma | (0.32) | 8 per month | 0.00 | (0.23) | 6.76 | (7.92) | 16.62 | |
ZNTL | Zentalis Pharmaceuticals Llc | 0.16 | 8 per month | 5.10 | 0.02 | 11.41 | (8.20) | 33.76 | |
SNDX | Syndax Pharmaceuticals | (0.35) | 6 per month | 0.00 | (0.09) | 4.02 | (4.81) | 34.00 | |
PTGX | Protagonist Therapeutics | 0.67 | 9 per month | 0.00 | (0.07) | 3.42 | (3.82) | 16.19 | |
MRSN | Mersana Therapeutics | 0.18 | 8 per month | 4.75 | 0.13 | 12.03 | (9.72) | 32.25 |
Eterna Therapeutics Additional Predictive Modules
Most predictive techniques to examine Eterna price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Eterna using various technical indicators. When you analyze Eterna charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
About Eterna Therapeutics Predictive Indicators
The successful prediction of Eterna Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Eterna Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Eterna Therapeutics based on analysis of Eterna Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Eterna Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Eterna Therapeutics's related companies. 2020 | 2023 | 2024 (projected) | Dividend Yield | 4.4E-5 | 0.001673 | 0.001803 | Price To Sales Ratio | 140.66 | 126.6 | 132.93 |
Story Coverage note for Eterna Therapeutics
The number of cover stories for Eterna Therapeutics depends on current market conditions and Eterna Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Eterna Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Eterna Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Eterna Therapeutics Short Properties
Eterna Therapeutics' future price predictability will typically decrease when Eterna Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Eterna Therapeutics often depends not only on the future outlook of the potential Eterna Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eterna Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 5.3 M | |
Cash And Short Term Investments | 7.6 M |
Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |